TMCI241220C20000
- 0.10
- 0.000.00%
Treace Medical Concepts Newsroom
Treace Medical Concepts Analyst Ratings
BTIG Maintains Treace Medical Concepts(TMCI.US) With Hold Rating
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Raises Target Price to $7
Treace Medical Concepts (TMCI) Gets a Hold From BTIG
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Fresenius Medical Care (FMS) and Treace Medical Concepts (TMCI)
Truist Financial Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Cuts Target Price to $6
Treace Medical Concepts Analyst Ratings
Morgan Stanley Maintains Treace Medical Concepts(TMCI.US) With Hold Rating, Maintains Target Price $7.5
Maintaining Hold on Treace Medical Concepts Amidst Stable Growth and Anticipated Product Launches
Treace Medical Concepts Analyst Ratings
Truist Financial Sticks to Their Hold Rating for Treace Medical Concepts (TMCI)
Truist Raises Price Target on Treace Medical Concepts to $9 From $7, Maintains Hold Rating
Treace Medical Concepts Analyst Ratings
Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
UBS Downgrades Treace Medical, Cites Increasing Competition
Treace Medical Concepts Analyst Ratings
Treace Medical Concepts Analyst Ratings
Morgan Stanley Downgrades Treace Medical Concepts to Equal-Weight, Lowers Price Target to $5.5
UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating